Hyderabad-based Lee Pharma has entered into an settlement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to fabricate and commercialise 2-Deoxy-D-Glucose (2-DG) used to deal with Covid sufferers, a press release stated on Wednesday.
An built-in pharmaceutical firm, Lee Pharma entered into the non-exclusive licensing settlement for the synthesis of 2-DG, just lately developed by DRDO and Dr Reddy’s Laboratories.
The drug has acquired approval to be used in COVID-19 sufferers. It has been discovered to assist velocity up restoration and scale back oxygen dependence, and Dr. Reddy”s Laboratories has launched the drug within the type of sachets.
Lee Pharma knowledgeable that they’d file the appliance for getting the approval from the drug regulator.
Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility positioned at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh, which has the accreditation by international regulatory companies, the Council for Scientific and Industrial Research (CSIR) stated in a press release.
Srivari Chandrashekar, Director CSIR-IICT stated, “There is role of CSIR in development of 2-DG, as CSIR-CCMB tested the drug on SARS-CoV-2 viral cultures”.
“The CSIR has been engaged in development of drugs for treatment of COVID-19 and has undertaken many clinical trials for repurposed drugs. Additionally, this agreement with Lee Pharma Ltd is towards increasing affordable therapeutic options for treatment of COVID-19,” he stated.
(Except for the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)